SGLT2 Inhibitors Comparison Table – Clinical Application

We've provided an SGLT2 inhibitors comparison table

Sodium-glucose co-transporter 2 inhibitors (SGLT2s) are becoming popular treatments for type 2 diabetes mellitus. While typically classified as diabetes medications, there is more and more research coming out for their benefits in cardiovascular health and heart failure. There are currently four SGLT2s on the market, all still available as brand-name only: canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro). We’ve provided an SGLT2 inhibitors comparison table at the end of the post.

SGLT2 inhibitors work by blocking the reabsorption of glucose in the proximal renal tubule, resulting in increased glucose excretion. This mechanism is responsible for the rare but potentially serious adverse effect of UTIs and other genital infections. Common sense tells us that an increased presence of glucose in the urine provides a hospitable environment for microorganisms. Patients should be warned about this and encouraged to have adequate fluid intake and good hygiene for prevention.

Initially approved for type 2 diabetes alone, three of the currently available SGLT2s (canagliflozin, dapagliflozin, and empagliflozin) have now been approved for treatment in patients with both type 2 diabetes and CV disease.  In May 2020, dapagliflozin became the only SGLT2 approved by the FDA for use in heart failure. It is indicated in HFrEF patients with or without type 2 diabetes, which is also the first time an SGLT2 inhibitor has been approved for use in the treatment of patients regardless of diabetes status. The fourth, ertugliflozin, remains indicated only for use in the treatment of type 2 diabetes. I personally haven’t seen this agent used in clinical practice.

There is not a lot of head-to-head data comparing the various SGLT2 inhibitors. There is some evidence that suggests canagliflozin, specifically at the 300mg dose, may have slightly higher efficacy at lowering HbA1c, while meta-analysis data shows that there is no difference between agents in terms of weight loss nor reduction in systolic blood pressure. Cost can be an issue for patients, as these brand name drugs can be quite expensive, depending on insurance coverage. Formularies and the presence of concomitant CV disease or heart failure are the primary reasons a clinician will choose one SGLT2 over another. The SGLT2 Inhibitors Comparison Table below lays out the different indications.

AgentFDA IndicationsDosingOther considerations
T2DM + CV disease
100 – 300mg dailyRenally dosed (CI’ed GFR < 30)
Not recommended with hepatic impairment
T2DM + CV disease
Heart failure
5 – 10mg dailyCI’ed if GFR < 30 (T2DM)
Insufficient data for renal impairment in the setting of HF
May increase serum creatinine
T2DM + CV disease
10 – 25mg dailyDo not initiate with GFR < 45
CI’ed in ESRD
May increase LDL-C
ErtugliflozinT2DM5 – 15mg dailyDo not initiate/DC with GFR < 60
CI’ed if GFR <30
May increase LDL-C
*All SGLT2 inhibitors have the potential to cause hypotension, volume depletion, increased urinary frequency, serious GU infection, acute kidney injury, hypoglycemia, and hypersensitivity reactions. These factors should always be considered before initiating therapy in particular patient populations. Additionally, all advise consideration of holding for 3 days prior to surgery due to risk of hypoglycemia.

If you’d like to learn more about the pharmacology and adverse effects of these agents, check out this podcast on SGLT2 Inhibitors. If you are looking for more on diabetes, check out this post on which medications target pre- or post-prandial blood glucose.

This article was written by Meredith Grunig in collaboration with Eric Christianson, PharmD, BCPS, BCGP

Did you enjoy this blog post? Subscribers are emailed new blog posts TWICE per week! In addition, you’ll get access to the free giveaways below. Over 6,000 healthcare professionals have subscribed for our FREE Giveaways. Why haven’t you?!

Study Materials and Resources For Healthcare Professionals and Students – Amazon Books



FDA (December 2016). FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [Press release]. Retrieved from

American Journal of Managed Care (May 2020) FDA Approves Dapagliflozin to Treat Heart Failure, Breaking New Ground in SGLT2 Competition [Press release]. Retrieved from’s,if%20diabetes%20is%20not%20present.

Shyangdan DS, et al. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016 Feb 24; 6(2). 

Johnston R, Uthman O, Cummins E, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation [published correction appears in Health Technol Assess. 2018 Feb;21(2):219-220]. Health Technol Assess. 2017;21(2):1-218. 



  1. Titration of GLP-1 Agonists (Table) - Med Ed 101 - […] Did you find this article on the titration of GLP-1 Agonists helpful? You’ll probably like this SGLT-2 comparison table.…
  2. Reasons For Duplicate SSRIs - Med Ed 101 - […] taking dapagliflozin. I would certainly want to check the indication on this medication as the SGLT2 inhibitors are well…

Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Written By Eric Christianson

July 12, 2020

Study Materials For Pharmacists


Explore Categories